Long Position on VCEL @ $18.80 on 7/3/2019 (Momentum)

Vericel Corporation (VCEL) is a commercial-stage biopharmaceutical company.

The firm researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets.

It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. 

On May 8th, Vericel Corproation (VCEL) reported a 1st Quarter March 2019 loss of $0.07 per share on revenue of $21.8 million. The consensus estimate was a loss of $0.07 per share on revenue of $22.6 million. Revenue grew 21.0% on a year-over-year basis.

The company said it expects 2019 revenue of $110.0 million to $114.0 million. The company's previous guidance was revenue of $108.0 million to $112.0 million and the current consensus estimate is revenue of $112.4 million for the year ending December 31, 2019..

Shares have formed a bullish "cup and handle" and are expected to move higher from this formation. Higher share prices are expected for this stock.

Entry Point: $18.80

Stop Loss: $17.60

Trading Range: $8.95 to $21.00

Target Price: $20.70

Updates

9/4/2019 9:37:09 AM

VCEL closed at $16

Position closed on 9/4/2019 at price of $16.00 with a -14.89% loss in 63 days.

Back to Portfolio